Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenacemide SCHEMBL35118 | 0.84 | MEN1 (0.61) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| SCHEMBL699925 | 0.83 | MEN1 (0.71) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| SCHEMBL3729853 | 0.83 | GAA (0.63) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| Phenacemide SCHEMBL23234284 | 0.82 | MEN1 (0.59) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| SCHEMBL16587378 | 0.82 | MEN1 (0.59) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| SCHEMBL17993503 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| SCHEMBL13926590 | 0.81 | GAA (0.56) | ALDH1A1LMNAKMT2AGAAHTT | |
| SCHEMBL3269788 | 0.81 | MEN1 (0.57) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| SCHEMBL14817549 | 0.81 | ALDH1A1 (0.61) | ALDH1A1LMNAKMT2AMEN1HDAC8 | |
| SCHEMBL6470572 | 0.79 | MEN1 (0.65) | ALDH1A1LMNAKMT2AMEN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100415720-C | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN BREWERY (JP) | 2008-09-03 | — | — | CN | claimed |
| CN-101189241-A | Thienopyridine derivative, quinoline derivative, and quinazoline derivative having c-Met autophosphorylation inhibiting activity | KIRIN PHARMA KK (JP) | 2008-05-28 | — | — | CN | claimed |
| CN-1553899-A | Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds | ������������ʽ���� | 2004-12-08 | — | — | CN | claimed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| EP-1989211-A2 | HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| CN-1906166-A | Novel pyridine derivative and pyrimidine derivative (1) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906167-A | Novel pyridine derivative and pyrimidine derivative (2) | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| WO-2006010264-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2006-02-02 | — | — | WO | disclosed |
| CN-1553899-A | Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds | ������������ʽ���� | 2004-12-08 | — | — | CN | disclosed |
| US-4891069-A | CATALYST FOR REDUCTION OF METAL COMPOUND BY GENERATED HYDROGEN | TECHNO INSTRUMENTS INVESTMENTS 1983 LTD. (IL) | 1990-01-02 | — | — | US | disclosed |
| US-4790912-A | ELECTROLYTICALLY-GENERATED HYDROGEN AND CATALYST CONVERT METAL SALT IN BATH TO METAL | TECHNO-INSTRUMENTS INVESTMENTS LTD. (IL) | 1988-12-13 | — | — | US | disclosed |
| US-4749449-A | PLATING ON CATALYZED THROUGH HOLE WALL IN PATTERENED CONDUCTIVE AND INSULATING LAYERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | ALDH1A1 1649/4885LMNA 4411/4885KMT2A 3391/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | ALDH1A1 1649/4885LMNA 4411/4885KMT2A 3391/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | ALDH1A1 1649/4885LMNA 4411/4885KMT2A 3391/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | ALDH1A1 1821/4885LMNA 4480/4885KMT2A 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.